MarketPeel
Insider Trading Intelligence
Pricing
…
MM

Michael F. Maclean

RNA
CHIEF FINANCIAL OFFICER · ATRIUM THERAPEUTICS, INC. · CIK 0001383731
FILING MIX · LIFETIME40%/60%
BUYS
19
SELLS
29
TOTAL VALUE
$17.73M
COMPANIES
3
ACTIVE SINCE
Feb 2021
HOLDINGS NOW
115,290
AVG SELL PX
$36.92
TRADE KIND
SHOWING 48 / 48
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
No backtest data available for Michael F. Maclean. Backtests are computed for purchase (P) and sale (S) transactions with resolvable price history.
Holdings over time
RNA · 59,290 shares · as of Jan 21, 2026
061,107122,214183,320244,42720222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 19 buys / 29 sellsCOVERAGE · 22 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CAMP
CAMP4 THERAPEUTICS CORP
PURCHASEGRANT
Stock grant
56,000——56,000Apr 1, 2026Apr 3, 2026 ↗View →
RNAM
AVIDITY BIOSCIENCES, INC.
SALE
Chief Financial Officer
50,000——0Feb 27, 2026Feb 27, 2026 ↗View →
RNAM
AVIDITY BIOSCIENCES, INC.
SALE
Chief Financial Officer
131,250——0Feb 27, 2026Feb 27, 2026 ↗View →
RNAM
AVIDITY BIOSCIENCES, INC.
SALE
Chief Financial Officer
60,125——0Feb 27, 2026Feb 27, 2026 ↗View →
RNAM
AVIDITY BIOSCIENCES, INC.
SALE
Chief Financial Officer
148,000——0Feb 27, 2026Feb 27, 2026 ↗View →
RNAM
AVIDITY BIOSCIENCES, INC.
SALE
Chief Financial Officer
106,000——0Feb 27, 2026Feb 27, 2026 ↗View →
RNAM
AVIDITY BIOSCIENCES, INC.
SALE
Chief Financial Officer
133,977——0Feb 27, 2026Feb 27, 2026 ↗View →
RNAM
AVIDITY BIOSCIENCES, INC.
SALE
Chief Financial Officer
92,000——0Feb 27, 2026Feb 27, 2026 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,807$72.45$130.9K62,025Jan 21, 2026Jan 23, 2026 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,735$72.45$198.2K59,290Jan 21, 2026Jan 23, 2026 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,974$72.23$142.6K63,832Jan 7, 2026Jan 9, 2026 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
30,914$42.73$1.32M65,806Aug 6, 2025Aug 15, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
7,935$31.06$246.4K96,720Mar 20, 2025Mar 21, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,622$28.59$46.4K106,320Jan 21, 2025Jan 23, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,665$28.59$47.6K104,655Jan 21, 2025Jan 23, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,000——107,942Jan 6, 2025Jan 8, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
50,000——50,000Jan 6, 2025Jan 8, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
11,151$32.66$364.2K82,942Dec 18, 2024Dec 19, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
65,182$8.82$574.9K159,275Nov 6, 2024Nov 8, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
Chief Financial Officer
65,182——0Nov 6, 2024Nov 8, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
Chief Financial Officer
13,875——60,125Nov 6, 2024Nov 8, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
13,875$6.57$91.2K107,968Nov 6, 2024Nov 8, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
65,182$45.33$2.95M94,093Nov 6, 2024Nov 8, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
27,262$46.22$1.26M94,093Nov 6, 2024Nov 8, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
13,875$45.33$629.0K94,093Nov 6, 2024Nov 8, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
11,510$44.00$506.4K96,355Sep 23, 2024Sep 23, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,000——107,865Sep 19, 2024Sep 23, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,000——121,355Sep 19, 2024Sep 23, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
11,228$39.13$439.3K57,865Jun 18, 2024Jun 20, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,000——82,865Jun 17, 2024Jun 20, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,000——69,093Jun 17, 2024Jun 20, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
Chief Financial Officer
104,245——65,182Jun 12, 2024Jun 14, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
104,245$35.72$3.72M44,093Jun 12, 2024Jun 14, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
104,245$8.82$919.4K148,338Jun 12, 2024Jun 14, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
Chief Financial Officer
75,000——169,427May 14, 2024May 16, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
75,000$28.28$2.12M44,093May 14, 2024May 16, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
75,000$8.82$661.5K119,093May 14, 2024May 16, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
40,000$8.82$352.8K84,093Mar 13, 2024Jan 23, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
40,000$24.52$980.8K44,093Mar 13, 2024Jan 23, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
Chief Financial Officer
40,000——244,427Mar 13, 2024Jan 23, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,616$10.13$16.4K16,884Jan 22, 2024Jan 23, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
22,500——27,209Jan 20, 2024Jan 23, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
106,000——106,000Jan 20, 2024Jan 23, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
74,000——74,000Sep 11, 2023Sep 12, 2023 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
18,500——21,852Jan 20, 2023Jan 24, 2023 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
148,000——148,000Jan 20, 2023Jan 24, 2023 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
131,250——131,250Jan 21, 2022Mar 15, 2022 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
92,000——92,000Feb 2, 2021Feb 4, 2021 ↗View →
Other insiders · RNA
Loading peer insiders…
About this filer
CIK 0001383731
ROLE
Chief Financial Officer
PRIMARY
RNA
COMPANIES
3
ACTIVE SINCE
Feb 2021
MARKETPEEL · /INSIDER/0001383731DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback